Genome & Company
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The c… Read more
Genome & Company - Asset Resilience Ratio
Genome & Company (314130) has an Asset Resilience Ratio of 12.37% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Genome & Company's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Genome & Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩16.92 Billion | 12.37% |
| Total Liquid Assets | ₩16.92 Billion | 12.37% |
Asset Resilience Insights
- Moderate Liquidity: Genome & Company has 12.37% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Genome & Company Industry Peers by Asset Resilience Ratio
Compare Genome & Company's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Genome & Company (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Genome & Company.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 52.40% | ₩77.20 Billion | ₩147.33 Billion | +1.55pp |
| 2023-12-31 | 50.85% | ₩82.41 Billion | ₩162.06 Billion | -7.82pp |
| 2022-12-31 | 58.67% | ₩101.49 Billion | ₩173.00 Billion | +28.70pp |
| 2021-12-31 | 29.96% | ₩41.11 Billion | ₩137.22 Billion | -- |